Eveliqure is a clinical-stage bio-technology company developing an oral broad-coverage vaccine against diarrhoeal diseases for travelers and young children living in disease endemic regions of the world.

The clinical stage vaccine ShigETEC - targeting Shigella and entero-toxigenic E. coli (ETEC) infections - is being evaluated in Phase 1b trial with small children in Bangladesh and in a human infectious model (Phase 2 efficacy study) in the US.

CALYXHA is an innovative biotech company developing novel small molecule anti-inflammatory drugs.

CALYXHA’s lead drug candidate targets multiple inflammatory diseases, with robust efficacy data in inhalative asthma models.  The Company is currently in preclinical development GMP manufacture) and ready to enter IND enabling studies.

Algonist is a clinical stage biotech company developing novel non-opioid and non-addictive analgesics against chronic pain.

Algonist’s lead program, ALG-1 has encouraging FIH clinical study. The ongoing Phase 1a single dose ascending study is testing higher doses of the lead compound SZV-1287.  

TAG Therapeutics is a young start-up growing out from CEBINA’s acceleration program, DanubeLabs.

TAG’s highly innovative ASO-based technology is addressing telomere pathologies, and addresses both rare genetic diseases and age-related disorders, Idiopathic Pulmonary Fibrosis (IPF) being the first clinical target.

MAG – Molecular Architecture Group – takes a pragmatic and visionary approach to drug design. Leveraging chemistry, molecular-structural biology as well as computational prediction, MAG-LAB is supporting early drug development of its partners and fuel its own drug discovery pipeline.